VIDEO: CAR-T 'extremely effective' in myeloma treatment

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

CAR-T has been extremely effective. So in general, almost everybody responds, even at a late stage of the disease. The study done was in people who had, on average, six lines of treatment. And even at this stage, with one of the CAR-T product, 98% patients responded, 80% achieving what we call complete remission. So incredibly effective in all comers. So a question that is probably more appropriate is which patients are not candidate? And the reason I say this is because, for example, for transplant, autologous transplant, we try to have younger patients, less than 70 or certain heart disease and/or other conditions are excluded. In CAR-T, we have treated patients up to 80 without major issue. We have been able to treat patients with kidney functions, may not be totally normal. We've been able to treat patients who cardiac functions may not be as good as we require for transplant. And so it is applicable to a very broad spectrum of patients who have otherwise average health and are able to take other treatments. And so the good positive news about CAR-T cell set, it's very broadly applicable to all different patients subgroups with multiple myeloma. Patients who may not be good candidate will be decided, based on individual applications. And I think there will be physician's decision to some extent. So for example, somebody who's in a heavy doses of immunosuppressive treatment, that's where CAR T-cell may not work. It's not a bad thing, but it may not work. And so I think we keep a broad eligibility and consideration for all patients for CAR-T and find some occasional specific reasons not to do it. But otherwise, I would consider for all patients.